This is a randomized, three-part, open-label trial of grazoprevir (MK-5172) (100 mg) and MK-3682 (300 mg or 450 mg), with either elbasvir (MK-8742) (50 mg) or MK-8408 (60 mg), and with or without ribavirin (RBV), in treatment-naïve (TN) and treatment-experienced (TE) cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) participants with chronic HCV genotype (GT) 1 or GT2 infection. Part A will consist of 8 arms to evaluate the safety of dose combinations. In Part B, participants will take 2 MK-3682B fixed dose combination (FDC) tablets once daily (q.d.) by mouth, with or without twice-daily (b.i.d.) RBV (200 mg capsules; weight-based dosing). Participants who relapse following completion of therapy in Part A will be offered the option of retreatment with 16 weeks of MK-3682B with RBV in Part C (data obtained from Part C will not be used in the analysis of outcome measures).
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.